Explore

Trendline Trendline
D3 Bio Secures $108 Million to Advance Oncology Clinical Programs

D3 Bio Secures $108 Million to Advance Oncology Clinical Programs

D3 Bio Secures $108 Million to Advance Oncology Clinical Programs
Trendline Trendline
cGMP Manufacturing Market Expands with Biopharmaceutical Advancements

cGMP Manufacturing Market Expands with Biopharmaceutical Advancements

cGMP Manufacturing Market Expands with Biopharmaceutical Advancements
Rapid Read Rapid Read
CARsgen's CAR-T Product Zevor-Cel Gains Inclusion in China's Health Insurance Catalogue, Enhancing Accessibility for Multiple Myeloma Patients

CARsgen's CAR-T Product Zevor-Cel Gains Inclusion in China's Health Insurance Catalogue, Enhancing Accessibility for Multiple Myeloma Patients

CARsgen Therapeutics Holdings Limited has announced that its CAR-T product, zevorcabtagene autoleucel (zevor-cel), has been included in China's Commercial Health Insurance Innovative Drug Catalogue. This inclusion is significant for the treatment of relapsed/refractory multiple myeloma. The Innovative Drug Catalogue, established by the National Healthcare Security Administration, aims to support highly innovative drugs that offer substantial clinical benefits. Zevor-cel, a Category 1 innovative biological product, was approved by the National Medical Products Administration in February 2024. It is designed for adult patients who have not responded to at least three prior therapies. CARsgen has partnered with Huadong Medicine Co., Ltd. for the commercialization of zevor-cel in mainland China, and the product has already seen significant uptake, with 170 confirmed orders from January to September 2025.
Rapid Read Rapid Read
CARsgen Presents Promising Data on BCMA CAR-T Therapy for Multiple Myeloma at ASH Meeting

CARsgen Presents Promising Data on BCMA CAR-T Therapy for Multiple Myeloma at ASH Meeting

CARsgen Therapeutics Holdings Limited has announced promising clinical data for its allogeneic BCMA-targeted CAR T-cell therapy, CT0596, at the 2025 American Society of Hematology (ASH) Annual Meeting. The study involved eight patients with relapsed/refractory multiple myeloma, showing that six achieved a partial response or better, with three achieving complete responses. The therapy demonstrated a manageable safety profile, with no severe cytokine release syndrome or neurotoxicity observed. The trial is in the dose-exploration phase, with plans for a Phase 1b registrational study in 2026.
Rapid Read Rapid Read
Binnopharm Group and Mabwell to Localize Dupilumab Production in Russia

Binnopharm Group and Mabwell to Localize Dupilumab Production in Russia

Binnopharm Group, in collaboration with China's Mabwell, is set to localize the production of dupilumab in Russia. Dupilumab is a biopharmaceutical drug used to treat atopic dermatitis and bronchial asthma. The production will take place at Binnopharm's facility in Zelenograd, with the first products expected to launch in early 2026. This partnership marks a significant step in expanding biopharmaceutical manufacturing capabilities in Russia, with Binnopharm having exclusive rights to produce and sell certain Mabwell drugs.
Rapid Read Rapid Read
CARsgen Presents Promising Data for Allogeneic CAR-T Therapy CT0596 in Multiple Myeloma

CARsgen Presents Promising Data for Allogeneic CAR-T Therapy CT0596 in Multiple Myeloma

CARsgen Therapeutics has announced clinical data from its allogeneic BCMA-targeted CAR-T therapy, CT0596, for relapsed/refractory multiple myeloma. Presented at the 2025 ASH Annual Meeting, the trial involved eight patients, with six achieving a partial response or better. The therapy demonstrated a manageable safety profile, with no severe adverse events reported. CT0596 is developed using CARsgen's THANK-u Plus platform and is being evaluated for other plasma cell malignancies and autoimmune diseases. The company plans to initiate a Phase 1b registrational study in 2026.
Trendline Trendline
Zai Lab's Medicines Renewed in China's National Reimbursement Drug List, Enhancing Patient Access

Zai Lab's Medicines Renewed in China's National Reimbursement Drug List, Enhancing Patient Access

Zai Lab's Medicines Renewed in China's National Reimbursement Drug List, Enhancing Patient Access
Rapid Read Rapid Read
AstraZeneca's CAR-T Therapy AZD0120 Shows High Efficacy in Multiple Myeloma Trials

AstraZeneca's CAR-T Therapy AZD0120 Shows High Efficacy in Multiple Myeloma Trials

AstraZeneca has reported promising results from its phase 1b/2 DURGA-1 trial of AZD0120, a dual BCMA and CD19-directed CAR-T therapy for relapsed/refractory multiple myeloma. The trial, conducted in the US, showed an objective response rate of 96% and a complete response rate of 78.3%. The therapy was well-tolerated, with no severe adverse events, and is suitable for outpatient administration. AZD0120 is based on Gracell's FasTCAR platform, allowing for rapid manufacturing. The therapy is also being tested for other conditions, including systemic lupus erythematosus and amyloid light chain amyloidosis.
Trendline Trendline
Gilead's Kite Unit Prepares Anito-cel Filing Following Promising iMMagine-1 Trial Results

Gilead's Kite Unit Prepares Anito-cel Filing Following Promising iMMagine-1 Trial Results

Gilead's Kite Unit Prepares Anito-cel Filing Following Promising iMMagine-1 Trial Results
Rapid Read Rapid Read
China Invests $80 Billion in Overseas Clean Technology Amid U.S. Tariffs

China Invests $80 Billion in Overseas Clean Technology Amid U.S. Tariffs

Chinese firms have invested approximately $80 billion in overseas clean technology over the past year, according to a report by Climate Energy Finance. This investment surge is driven by a need to address a supply glut in green technology products like solar panels and batteries. The report highlights that many countries have increased their cooperation with China in response to U.S. tariffs imposed by President Trump. China's foreign investments in clean energy infrastructure are creating new markets for its products, with significant projects in regions such as Southeast Asia, the Middle East, and Africa. Notable projects include a green hydrogen initiative in Nigeria and a battery factory in Indonesia.
AP News AP News
Trump approves sale of more advanced Nvidia computer chips used in AI to China

Trump approves sale of more advanced Nvidia computer chips used in AI to China

President Donald Trump says he will allow Nvidia to sell its H200 computer chip used in the development of artificial intelligence to “approved customers” in China
Rapid Read Rapid Read
XCMG Ships Mining Trucks to Simandou Project, Strengthening Sino-Guinea Partnership

XCMG Ships Mining Trucks to Simandou Project, Strengthening Sino-Guinea Partnership

XCMG Machinery has begun shipping a fleet of 230-ton diesel-electric drive XDE260 mining trucks from its manufacturing base in Xuzhou, China, to the SimFer operated mine in Guinea, West Africa. This shipment is part of a major equipment supply contract valued at nearly RMB 800 million, which includes large-capacity mining trucks and auxiliary equipment. The Simandou iron ore project, operated by a joint venture including Rio Tinto and the Government of Guinea, represents a significant collaboration between Chinese and international partners. XCMG's delivery underscores its commitment to providing technologically advanced and environmentally friendly mining solutions.